EDP Sciences logo
Search
Menu
All issues Volume 38 / No 2 (March-April 2007) Vet. Res., 38 2 (2007) 299-318 References
Open Access
Issue
Vet. Res.
Volume 38, Number 2, March-April 2007
Respiratory viruses of domestic animals
Page(s) 299 - 318
DOI https://doi.org/10.1051/vetres:2006054
Published online 13 February 2007
How to cite this article Vet. Res. (2007) 299-318
References of  Vet. Res. 38 (2007) 299-318
  1. Andrewes C.H., Harisijades S., Propagation of myxoma virus in one-day old mice, Br. J. Exp. Pathol. (1955) 36:18-21 [PubMed].
  2. Andrewes C.H., Chaproniere D.M., Propagation of rabbit myxoma and fibroma viruses in a guinea pig sarcoma, Virology (1957) 4:346-350 [CrossRef] [PubMed].
  3. Baeuerle P.A., I$\kappa$B-NF-$\kappa$B structures: at the interface of inflammation control, Cell (1998) 95:729-731 [CrossRef] [PubMed].
  4. Barclay A.N., Wright G.J., Brooke G., Brown M.H., CD200 and membrane protein interactions in the control of myeloid cells, Trends Immunol. (2002) 23:285-290 [CrossRef] [PubMed].
  5. Barrett J.W., Cao J.X., Hota-Mitchell S., McFadden G., Immunomodulatory proteins of myxoma virus, Semin. Immunol. (2001) 13:73-84 [CrossRef] [PubMed].
  6. Barry M., Hnatiuk S., Mossman K., Lee S.F., Boshkov L., McFadden G., The myxoma virus M-T4 gene encodes a novel RDEL-containing protein that is retained within the endoplasmic reticulum and is important for the productive infection of lymphocytes, Virology (1997) 239:360-377 [CrossRef] [PubMed].
  7. Bates P.W., Miyamoto S., Expanded nuclear roles for I$\kappa$Bs, Sci. STKE (2004) 12:pe48.
  8. Best S.M., Collins S.V., Kerr P.J., Coevolution of host and virus: cellular localization of virus in myxoma virus infection of resistant and susceptible European rabbits, Virology (2000) 277:76-91 [CrossRef] [PubMed].
  9. Best S.M., Kerr P.J., Coevolution of host and virus: the pathogenesis of virulent and attenuated strains of myxoma virus in resistant and susceptible European rabbits, Virology (2000) 267:36-48 [CrossRef] [PubMed].
  10. Boomker J.M., Luttikhuizen D.T., Veninga H., de Leij L.F., The T.H., de Haan A., van Luyn M.J., Harmsen M.C., The modulation of angiogenesis in the foreign body response by the poxviral protein M-T7, Biomaterials (2005) 26:4874-4881 [CrossRef] [PubMed].
  11. Cameron C., Hota-Mitchell S., Chen L., Barrett J., Cao J.X., Macaulay C., Willer D., Evans D., McFadden G., The complete DNA sequence of myxoma virus, Virology (1999) 264:298-318 [CrossRef] [PubMed].
  12. Cameron C.M., Barrett J.W., Liu L., Lucas A.R., McFadden G., Myxoma virus M141R expresses a viral CD200 (vOX-2) that is responsible for down-regulation of macrophage and T-cell activation in vivo, J. Virol. (2005) 79:6052-6067 [CrossRef] [PubMed].
  13. Cameron C.M., Barrett J.W., Mann M., Lucas A., McFadden G., Myxoma virus M128L is expressed as a cell surface CD47-like virulence factor that contributes to the downregulation of macrophage activation in vivo, Virology (2005) 337:55-67 [CrossRef] [PubMed].
  14. Camus-Bouclainville C., Fiette L., Bouchiha S., Pignolet B., Counor D., Filipe C., Gelfi J., Messud-Petit F., A virulence factor of myxoma virus colocalizes with NF-$\kappa$B in the nucleus and interferes with inflammation, J. Virol. (2004) 78:2510-2516 [CrossRef] [PubMed].
  15. Carter G.C., Law M., Hollinshead M., Smith G.L., Entry of the vaccinia virus intracellular mature virion and its interactions with glycosaminoglycans, J. Gen. Virol. (2005) 86:1279-90 [CrossRef] [PubMed].
  16. Chaproniere D.M., Andrewes C.H., Cultivation of rabbit myxoma and fibroma viruses in tissues of nonsusceptible hosts, Virology (1957) 4:351-365 [CrossRef] [PubMed].
  17. Chen Z.J., Ubiquitin signalling in the NF-$\kappa$B pathway, Nat. Cell Biol. (2005) 7:758-765 [CrossRef] [PubMed].
  18. Chung C.S., Hsiao J.C., Chang Y.S., Chang W., A27L protein mediates vaccinia virus interaction with cell surface heparan sulfate, J. Virol. (1998) 72:1577-1585 [PubMed].
  19. Dai E., Guan H., Liu L., Little S., McFadden G., Vaziri S., Cao H., Ivanova I.A., Bocksch L., Lucas A., Serp-1, a viral anti-inflammatory serpin, regulates cellular serine proteinase and serpin responses to vascular injury, J. Biol. Chem. (2003) 278:18563-18572 [CrossRef] [PubMed].
  20. DiGiacomo R.F., Mare C.J., Viral diseases, in: Manning P.J., Ringler D.H., Newcomer C.E. (Eds.), The biology of the laboratory rabbit, 2nd ed., Academic Press, San Diego, 1994, p. 171-183.
  21. Everett H., Barry M., Lee S.F., Sun X., Graham K., Stone J., Bleackley R.C., McFadden G., M11L: a novel mitochondria-localized protein of myxoma virus that blocks apoptosis of infected leukocytes, J. Exp. Med. (2000) 191:1487-1498 [CrossRef] [PubMed].
  22. Everett H., McFadden G., Viral proteins and the mitochondrial apoptotic checkpoint, Cytokine Growth Factor Rev. (2001) 12:181-188 [CrossRef] [PubMed].
  23. Everett H., McFadden G., Viruses and apoptosis: meddling with mitochondria, Virology (2001) 288:1-7 [CrossRef] [PubMed].
  24. Everett H., Barry M., Sun X., Lee S.F., Frantz C., Berthiaume L.G., McFadden G., Bleackley R.C., The myxoma poxvirus protein, M11L, prevents apoptosis by direct interaction with the mitochondrial permeability transition pore, J. Exp. Med. (2002) 196:1127-1139 [CrossRef] [PubMed].
  25. Everett H., McFadden G., Poxviruses and apoptosis: a time to die, Curr. Opin. Microbiol. (2002) 5:395-402 [CrossRef] [PubMed].
  26. Fenner F., Changes in the mortality-rate due to myxomatosis in the Australian wild rabbit, Nature (1953) 172:228-230 [CrossRef] [PubMed].
  27. Fenner F., Woodroofe G.M., The pathogenesis of infectious myxomatosis; the mechanism of infection and the immunological response in the European rabbit (Oryctolagus cuniculus), Br. J. Exp. Pathol. (1953) 34:400-411.
  28. Fenner F., Marshall I.D., A comparison of the virulence for European rabbits (Oryctolagus cuniculus) of strains of myxoma virus recovered in the field in Australia, Europe and America, J. Hyg. (Lond.) (1957) 5:149-191.
  29. Fenner F., Ratcliffe F., Myxomatosis, University Press, Cambridge, 1965.
  30. Fenner F., The Florey lecture, 1983, Biological control, as exemplified by smallpox eradication and myxomatosis, Proc. R. Soc. Lond. B Biol. Sci. (1983) 218:259-285 [PubMed].
  31. Fenner F., Adventures with poxviruses of vertebrates, FEMS Microbiol. Rev. (2000) 24:123-133 [PubMed].
  32. Fields B.N., Knipe D.M., Howley P.M., Griffin D.E., Fields' virology, 4th ed., Lippincott Williams & Wilkins, Philadelphia, 2001.
  33. Flohe L., Brigelius-Flohe R., Saliou C., Traber M.G., Packer L., Redox regulation of NF-$\kappa$B activation, Free Radic. Biol. Med. (1997) 22:1115-1126 [CrossRef] [PubMed].
  34. Garon C.F., Barbosa E., Moss B., Visualization of an inverted terminal repetition in vaccinia virus DNA, Proc. Natl. Acad. Sci. USA (1978) 75:4863-4867 [CrossRef] [PubMed].
  35. Graham K.A., Lalani A.S., Macen J.L., Ness T.L., Barry M., Liu L.Y., Lucas A., Clark-Lewis I., Moyer R.W., McFadden G., The T1/35kDa family of poxvirus-secreted proteins bind chemokines and modulate leukocyte influx into virus-infected tissues, Virology (1997) 229:12-24 [CrossRef] [PubMed].
  36. Guerin J.L., Gelfi J., Camus C., Delverdier M., Whisstock J.C., Amardeihl M.F., Py R., Bertagnoli S., Messud-Petit F., Characterization and functional analysis of Serp3: a novel myxoma virus-encoded serpin involved in virulence, J. Gen. Virol. (2001) 82:1407-1417 [PubMed].
  37. Guerin J.L., Gelfi J., Boullier S., Delverdier M., Bellanger F.A., Bertagnoli S., Drexler I., Sutter G., Messud-Petit F., Myxoma virus leukemia-associated protein is responsible for major histocompatibility complex class I and Fas-CD95 down-regulation and defines scrapins, a new group of surface cellular receptor abductor proteins, J. Virol. (2002) 76:2912-2923 [CrossRef] [PubMed].
  38. Haga I.R., Bowie A.G., Evasion of innate immunity by vaccinia virus, Parasitology Suppl. (2005) 130:S11-25.
  39. Hnatiuk S., Barry M., Zeng W., Liu L., Lucas A., Percy D., McFadden G., Role of the C-terminal RDEL motif of the myxoma virus M-T4 protein in terms of apoptosis regulation and viral pathogenesis, Virology (1999) 263:290-306 [CrossRef] [PubMed].
  40. Jackson E.W., Dorn C.R., Saito J.K., McKercher D.G., Absence of serological evidence of myxoma virus infection in humans exposed during an outbreak of myxomatosis, Nature (1966) 211:313-314 [CrossRef] [PubMed].
  41. Jiran E., Sladka M., Kunstyr I., Myxomatosis of rabbits - study of virus modification, Zentralbl. Veterinarmed. B (1970) 17:418-428 [PubMed].
  42. Johnston J.B., McFadden G., Poxvirus immunomodulatory strategies: current perspectives, J. Virol. (2003) 77:6093-6100 [CrossRef] [PubMed].
  43. Johnston J.B., Barrett J.W., Nazarian S.H., Goodwin M., Ricuttio D., Wang G., McFadden G., A poxvirus-encoded pyrin domain protein interacts with ASC-1 to inhibit host inflammatory and apoptotic responses to infection, Immunity (2005) 23:587-598 [CrossRef] [PubMed].
  44. Johnston J.B., Wang G., Barrett J.W., Nazarian S.H., Colwill K., Moran M., McFadden G., Myxoma virus M-T5 protects infected cells from the stress of cell cycle arrest through its interaction with host cell cullin-1, J. Virol. (2005) 79:10750-10763 [CrossRef] [PubMed].
  45. Kerr J.F., Wyllie A.H., Currie A.R., Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics, Br. J. Cancer (1972) 26:239-257 [PubMed].
  46. Kerr P.J., Best S.M., Myxoma virus in rabbits, Rev. Sci. Tech. (1998) 17:256-268 [PubMed].
  47. Kerr P., McFadden G., Immune responses to myxoma virus, Viral Immunol. (2002) 15:229-246 [PubMed].
  48. Krogstad A.P., Simpson J.E., Korte S.W., Viral diseases of the rabbit, Vet. Clin. North Am. Exot. Anim. Pract. (2005) 8:123-138 [PubMed].
  49. Lalani A.S., Graham K., Mossman K., Rajarathnam K., Clark-Lewis I., Kelvin D., McFadden G., The purified myxoma virus gamma interferon receptor homolog M-T7 interacts with the heparin-binding domains of chemokines, J. Virol. (1997) 71:4356-4363 [PubMed].
  50. Lalani A.S., McFadden G., Secreted poxvirus chemokine binding proteins, J. Leukoc. Biol. (1997) 62:570-576 [PubMed].
  51. Lalani A.S., Ness T.L., Singh R., Harrison J.K., Seet B.T., Kelvin D.J., McFadden G., Moyer R.W., Functional comparisons among members of the poxvirus T1/35kDa family of soluble CC-chemokine inhibitor glycoproteins, Virology (1998) 250:173-184 [CrossRef] [PubMed].
  52. Lalani A.S., Masters J., Graham K., Liu L., Lucas A., McFadden G., Role of the myxoma virus soluble CC-chemokine inhibitor glycoprotein, M-T1, during myxoma virus pathogenesis, Virology (1999) 256:233-245 [CrossRef] [PubMed].
  53. Lomas D.A., Evans D.L., Upton C., McFadden G., Carrell R.W., Inhibition of plasmin, urokinase, tissue plasminogen activator, and C1S by a myxoma virus serine proteinase inhibitor, J. Biol. Chem. (1993) 268:516-521 [PubMed].
  54. Lucas A., McFadden G., Secreted immunomodulatory viral proteins as novel biotherapeutics, J. Immunol. (2004) 173:4765-4774 [PubMed].
  55. Lucas A., McIvor D., McFadden G., Virus-encoded chemokine modulators as novel anti-inflammatory reagents, Chemokine Biology - Basic Research and Clinical Application, Vol. 1, 2006, pp. 165-182.
  56. Lun X., Yang W., Alain T., Shi Z.Q., Muzik H., Barrett J.W., McFadden G., Bell J., Hamilton M.G., Senger D.L., Forsyth P.A., Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas, Cancer Res. (2005) 65:9982-9990 [CrossRef] [PubMed].
  57. Macen J.L., Upton C., Nation N., McFadden G., SERP1, a serine proteinase inhibitor encoded by myxoma virus, is a secreted glycoprotein that interferes with inflammation, Virology (1993) 195:348-363 [CrossRef] [PubMed].
  58. Macen J.L., Graham K.A., Lee S.F., Schreiber M., Boshkov L.K., McFadden G., Expression of the myxoma virus tumor necrosis factor receptor homologue and M11L genes is required to prevent virus-induced apoptosis in infected rabbit T lymphocytes, Virology (1996) 218:232-237 [CrossRef] [PubMed].
  59. Mansouri M., Bartee E., Gouveia K., Hovey Nerenberg B.T., Barrett J., Thomas L., Thomas G., McFadden G., Fruh K., The PHD/LAP-domain protein M153R of myxomavirus is a ubiquitin ligase that induces the rapid internalization and lysosomal destruction of CD4, J. Virol. (2003) 77:1427-1440 [CrossRef] [PubMed].
  60. Marlier D., Vindevogel H., Poxless myxomatosis - Isolation of three strains in Belgium, Ann. Med. Vet. (1996) 140:343-346.
  61. Marlier D., Mainil J., Sulon J., Beckers J.F., Linden A., Vindevogel H., Study of the virulence of five strains of amyxomatous myxoma virus in crossbred New Zealand White/Californian conventional rabbits, with evidence of long-term testicular infection in recovered animals, J. Comp. Pathol. (2000) 122:101-113 [CrossRef] [PubMed].
  62. Marlier D., Mainil J., Linde A., Vindevogel H., Infectious agents associated with rabbit pneumonia: isolation of amyxomatous myxoma virus strains, Vet. J. (2000) 159:171-178 [CrossRef] [PubMed].
  63. McCabe V.J., Tarpey I., Spibey N., Vaccination of cats with an attenuated recombinant myxoma virus expressing feline calicivirus capsid protein, Vaccine (2002) 20:2454-2462 [CrossRef] [PubMed].
  64. McFadden G., Graham K., Ellison K., Barry M., Macen J., Schreiber M., Mossman K., Nash P., Lalani A., Everett H., Interruption of cytokine networks by poxviruses: lessons from myxoma virus, J. Leukoc. Biol. (1995) 57:731-738 [PubMed].
  65. McFadden G., Lalani A., Everett H., Nash P., Xu X., Virus-encoded receptors for cytokines and chemokines, Semin. Cell Dev. Biol. (1998) 9:359-368 [CrossRef] [PubMed].
  66. McFadden G., Poxvirus tropism, Nat. Rev. Microbiol. (2005) 3:201-213 [CrossRef] [PubMed].
  67. Messud-Petit F., Gelfi J., Delverdier M., Amardeilh M.F., Py R., Sutter G., Bertagnoli S., Serp2, an inhibitor of the interleukin-1$\beta$-converting enzyme, is critical in the pathobiology of myxoma virus, J. Virol. (1998) 72:7830-7839 [PubMed].
  68. Moss B., Poxviridae: The Viruses and their replication, in: Fields B.N., Knipe D.M., Howley P.M., Griffin D.E. (Eds.), Fields' virology, 4th ed., Lippincott Williams & Wilkins, Philadelphia, 2001, pp. 2849-2883.
  69. Moss B., Shisler J.L., Immunology 101 at poxvirus U: immune evasion genes, Semin. Immunol. (2001) 13:59-66 [CrossRef] [PubMed].
  70. Moss B., Poxvirus entry and membrane fusion, Virology (2006) 344:48-54 [CrossRef] [PubMed].
  71. Mossman K., Upton C., McFadden G., The myxoma virus-soluble interferon-$\gamma$ receptor homolog, M-T7, inhibits interferon-gamma in a species-specific manner, J. Biol. Chem. (1995) 270:3031-3038 [CrossRef] [PubMed].
  72. Mossman K., Nation P., Macen J., Garbutt M., Lucas A., McFadden G., Myxoma virus M-T7, a secreted homolog of the interferon-gamma receptor, is a critical virulence factor for the development of myxomatosis in European rabbits, Virology (1996) 215:17-30 [CrossRef] [PubMed].
  73. Mossman K., Lee S.F., Barry M., Boshkov L., McFadden G., Disruption of M-T5, a novel myxoma virus gene member of poxvirus host range superfamily, results in dramatic attenuation of myxomatosis in infected European rabbits, J. Virol. (1996) 70:4394-410 [PubMed].
  74. Nash P., Barrett J., Cao J.X., Hota-Mitchell S., Lalani A.S., Everett H., Xu X.M., Robichaud J., Hnatiuk S., Ainslie C., Seet B.T., McFadden G., Immunomodulation by viruses: the myxoma virus story, Immunol. Rev. (1999) 168:103-120 [PubMed].
  75. Nazarian S.H., McFadden G., Immune evasion by poxviruses, Future Medicine (2006) 1:123-132.
  76. Ng F.W., Nguyen M., Kwan T., Branton P.E., Nicholson D.W., Cromlish J.A., Shore G.C., p28 Bap31, a Bcl-2/Bcl-XL- and procaspase-8-associated protein in the endoplasmic reticulum, J. Cell Biol. (1997) 139:327-338 [CrossRef] [PubMed].
  77. Ng F.W., Shore G.C., Bcl-XL cooperatively associates with the Bap31 complex in the endoplasmic reticulum, dependent on procaspase-8 and Ced-4 adaptor, J. Biol. Chem. (1998) 273:3140-3143 [CrossRef] [PubMed].
  78. Opgenorth A., Graham K., Nation N., Strayer D., McFadden G., Deletion analysis of two tandemly arranged virulence genes in myxoma virus, M11L and myxoma growth factor, J. Virol. (1992) 66:4720-4731 [PubMed].
  79. Opgenorth A., Nation N., Graham K., McFadden G., Transforming growth factor alpha, Shope fibroma growth factor, and vaccinia growth factor can replace myxoma growth factor in the induction of myxomatosis in rabbits, Virology (1993) 192:701-709 [CrossRef] [PubMed].
  80. Petit F., Bertagnoli S., Gelfi J., Fassy F., Boucraut-Baralon C., Milon A., Characterization of a myxoma virus-encoded serpin-like protein with activity against interleukin-1 $\beta$-converting enzyme, J. Virol. (1996) 70:5860-5866 [PubMed].
  81. Saito J.K., McKercher D.G., Castrucci G., Attenuation of the myxoma virus and use of the living attenuated virus as an immunizing agent for myxomatosis, J. Infect. Dis. (1964) 114:417-428 [PubMed].
  82. Saurat P., Gilbert Y., Gagniere J.P., Étude d'une souche de virus myxomateux modifié, Rev. Med. Vet. (1978) 129:415-451.
  83. Schmelz M., Sodeik B., Ericsson M., Wolffe E.J., Shida H., Hiller G., Griffiths G., Assembly of vaccinia virus: the second wrapping cisterna is derived from the trans Golgi network, J. Virol. (1994) 68:130-147 [PubMed].
  84. Schreiber M., McFadden G., The myxoma virus TNF-receptor homologue (T2) inhibits tumor necrosis factor-alpha in a species-specific fashion, Virology (1994) 204:692-705 [CrossRef] [PubMed].
  85. Schreiber M., McFadden G., Mutational analysis of the ligand-binding domain of M-T2 protein, the tumor necrosis factor receptor homologue of myxoma virus, J. Immunol. (1996) 157:4486-4495 [PubMed].
  86. Schreiber M., Rajarathnam K., McFadden G., Myxoma virus T2 protein, a tumor necrosis factor (TNF) receptor homolog, is secreted as a monomer and dimer that each bind rabbit TNFalpha, but the dimer is a more potent TNF inhibitor, J. Biol. Chem. (1996) 271:13333-13341 [CrossRef] [PubMed].
  87. Seet B.T., Johnston J.B., Brunetti C.R., Barrett J.W., Everett H., Cameron C., Sypula J., Nazarian S.H., Lucas A., McFadden G., Poxviruses and immune evasion, Annu. Rev. Immunol. (2003) 21:377-423 [PubMed].
  88. Smith G.L., Vanderplasschen A., Extracellular enveloped vaccinia virus. Entry, egress, and evasion, Adv. Exp. Med. Biol. (1998) 440:395-414 [PubMed].
  89. Smith G.L., Law M., The exit of vaccinia virus from infected cells, Virus Res. (2004) 106:189-197 [CrossRef] [PubMed].
  90. Smith S.A., Kotwal G.J., Virokines: novel immunomodulatory agents, Expert. Opin. Biol. Ther. (2001) 1:343-357 [PubMed].
  91. Stanford M.M., McFadden G., The "supervirus"? Lessons from IL-4-expressing poxviruses, Trends Immunol. (2005) 26:339-345 [CrossRef] [PubMed].
  92. Su J., Wang G., Barrett J.W., Irvine T.S., Gao X., McFadden G., Myxoma virus M11L blocks apoptosis through inhibition of conformational activation of Bax at the mitochondria, J. Virol. (2006) 80:1140-1151 [CrossRef] [PubMed].
  93. Sypula J., Wang F., Ma Y., Bell J., McFadden G., Myxoma virus tropism in human tumour cells, Gene Ther. Mol. Biol. (2004) 8:103-114.
  94. Taylor J.M., Barry M., Near death experiences: poxvirus regulation of apoptotic death, Virology (2006) 344:139-150 [CrossRef] [PubMed].
  95. Turner P.C., Sancho M.C., Thoennes S.R., Caputo A., Bleackley R.C., Moyer R.W., Myxoma virus Serp2 is a weak inhibitor of granzyme B and interleukin-1$\beta$-converting enzyme in vitro and unlike CrmA cannot block apoptosis in cowpox virus-infected cells, J. Virol. (1999) 73:6394-6404 [PubMed].
  96. Upton C., Macen J.L., Wishart D.S., McFadden G., Myxoma virus and malignant rabbit fibroma virus encode a serpin-like protein important for virus virulence, Virology (1990) 179:618-631 [CrossRef] [PubMed].
  97. Upton C., Macen J.L., Schreiber M., McFadden G., Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence, Virology (1991) 184:370-382 [CrossRef] [PubMed].
  98. Upton C., Mossman K., McFadden G., Encoding of a homolog of the IFN-$\gamma$ receptor by myxoma virus, Science (1992) 258:1369-1372 [CrossRef].
  99. Van Beek E.M., Cochrane F., Barclay A.N., van den Berg T.K., Signal regulatory proteins in the immune system, J. Immunol. (2005) 175:7781-7787 [PubMed].
  100. Van Eijl H., Hollinshead M., Rodger G., Zhang W.H., Smith G.L., The vaccinia virus F12L protein is associated with intracellular enveloped virus particles and is required for their egress to the cell surface, J. Gen. Virol. (2002) 83:195-207 [PubMed].
  101. Vanderplasschen A., Smith G.L., A novel virus binding assay using confocal microscopy: demonstration that the intracellular and extracellular vaccinia virions bind to different cellular receptors, J. Virol. (1997) 71:4032-4041 [PubMed].
  102. Vanderplasschen A., Hollinshead M., Smith G.L., Intracellular and extracellular vaccinia virions enter cells by different mechanisms, J. Gen. Virol. (1998) 79:877-887 [PubMed].
  103. Wang G., Barrett J.W., Nazarian S.H., Everett H., Gao X., Bleackley C., Colwill K., Moran M.F., McFadden G., Myxoma virus M11L prevents apoptosis through constitutive interaction with Bak, J. Virol. (2004) 78:7097-7111 [CrossRef] [PubMed].
  104. Ward B.M., The longest micron; transporting poxviruses out of the cell, Cell. Microbiol. (2005) 7:1531-1538.
  105. Webb L.M., Alcami A., Virally encoded chemokine binding proteins, Mini Rev. Med. Chem. (2005) 5:833-848 [CrossRef] [PubMed].
  106. Zuniga M.C., Lessons in detente or know thy host: the immunomodulatory gene products of myxoma virus, J. Biosci. (2003) 28:273-285 [PubMed].